Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib + Sorafenib in R/R Hematologic Malignancies
NCT02270788Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crenolanib in acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Dose-limiting toxicity at Day 28 and Maximum tolerated dose at Day 28. Started Apr 2015; status: completed.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT02270788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02270788.